1. Home
  2. VVX vs MESO Comparison

VVX vs MESO Comparison

Compare VVX & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo V2X Inc.

VVX

V2X Inc.

HOLD

Current Price

$69.05

Market Cap

2.1B

ML Signal

HOLD

Logo Mesoblast Limited

MESO

Mesoblast Limited

HOLD

Current Price

$14.61

Market Cap

2.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VVX
MESO
Founded
2014
2004
Country
United States
Australia
Employees
N/A
81
Industry
Diversified Commercial Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
2.2B
IPO Year
2014
N/A

Fundamental Metrics

Financial Performance
Metric
VVX
MESO
Price
$69.05
$14.61
Analyst Decision
Hold
Strong Buy
Analyst Count
8
1
Target Price
$69.50
N/A
AVG Volume (30 Days)
526.2K
263.1K
Earning Date
05-04-2026
02-26-2026
Dividend Yield
N/A
N/A
EPS Growth
126.85
N/A
EPS
2.45
N/A
Revenue
$4,480,038,000.00
N/A
Revenue This Year
$7.21
$644.56
Revenue Next Year
$5.52
$38.70
P/E Ratio
$27.78
N/A
Revenue Growth
3.65
N/A
52 Week Low
$42.09
$9.61
52 Week High
$75.00
$21.50

Technical Indicators

Market Signals
Indicator
VVX
MESO
Relative Strength Index (RSI) 50.59 39.34
Support Level $52.66 $14.53
Resistance Level $71.40 $16.33
Average True Range (ATR) 2.29 0.45
MACD -0.46 -0.01
Stochastic Oscillator 30.51 17.54

Price Performance

Historical Comparison
VVX
MESO

About VVX V2X Inc.

V2X Inc is a U.S.-based company that provides services to the U.S. government. It operates as one segment and offers facility and logistics services and information technology mission support and engineering and digital integration services. The information technology and network communications capabilities consist of communications systems operations and maintenance, management and service support, systems installation and activation, system-of-systems engineering and software development, and mission support for the department of defense. The facility and logistics service include airfield management, ammunition management, civil engineering, communications, emergency services, life support activities, public works, security, transportation operations, and others.

About MESO Mesoblast Limited

Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.

Share on Social Networks: